Company overview
| Company | RevolKa Ltd. |
| Headquarter | 2-26-9 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan |
| Establish Date | April 7th, 2021 |
| Capital | 100 million yen (As of February 29, 2024) |
| Management | President and CEO Norio Hamamatsu, Ph.D. Board Director and CSO Mitsuo Umetsu, Ph.D. Board Director Ayumi Iwase Outside Board Director Fumihiro Nakamori, Ph.D. Outside Board Director Kenji Watatani, Ph.D. Corporate Auditor Naoya Onaka |
| Adviser | Technical Advisor Hikaru Nakazawa, Ph.D. Scientific Advisor Kouji Tsuda, Ph.D. Scientific Advisor Hahumi Nishi, Ph.D. Scientific Advisor Yutaka Saito, Ph.D. Strategy Advisor Kentaro Yoshimatsu, Ph.D. |
| Business Category | Development of highly functional proteins using AI |
| Number of Employees | 16（including officers and temporary employees) |
| Member Organizations | The Antibody Society of Japan Japan Bioindustry Association |
Origin of company name
"RevolKa" is derived from the Latin word for evolution (evolutio) and the Ainu word for raise (reska). Our company logo takes inspiration from the developing fetus and represents that to raise (R of reska) nurtures evolution (e of evolution) with care.
We have evolved the protein selected by life as a functional molecule into a frontier that could not be reached in nature by using evolutionary molecular engineering that mimics evolution in vitro using artificial intelligence technology as a guide. We will grow it as a functional molecule required by various fields focusing on medicine.
History
| April, 2021 | Established RevolKa Ltd. in Chuo-ku, Tokyo as a venture from Tohoku University |
| June, 2021 | Concluded a joint research agreement with Tohoku University |
| June, 2021 | Completed funding in the first seed round |
| January, 2022 | Opened Sendai Lab in Aoba Ward, Sendai City |
| January, 2022 | Completed funding in the second seed round |
| March, 2022 | Concluded a joint research agreement with Sumitomo Dainippon Pharma Co., Ltd. (now Sumitomo Pharma Co., Ltd.) |
| April, 2022 | Opened Tokyo Laboratory in Chuo-ku, Tokyo |
| May, 2022 | Completed Series A round of funding |
| September, 2022 | Opened US office in Cambridge, Massachusetts, USA |
| October, 2022 | Concluded a joint research agreement with Tokyo Medical and Dental University |
| November, 2022 | Relocated Tokyo Laboratory to Bunkyo-ku, Tokyo |
| July, 2023 | Relocated Head office to Bunkyo-ku, Tokyo |
| September, 2023 | Closed Tokyo Laboratory |
| January, 2024 | Completed Series A extension round of funding |
Co-founder
SHIRO KATAOKA
MITSUO UMETSU
HIKARU NAKAZAWA
Locations
RevolKa head office
2-26-9 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
From the nearest station
About 5-minutes walk from Exit 2 of "Hongo 3cyoume Station" on the Tokyo Metro Marunouti Line
Sendai Lab
6-6-40-401･305･309 Aoba, Aramaki, Aoba-ku, Sendai 980-8579, Japan
From the nearest station
About 2-minutes walk from the North Exit of "Aobayama Station" on Sendai Subway Tozai Line
About 2-minute walk from the south Exit of "Aobayama Station" on Sendai Subway Tozai Line
RevolKa U.S. Office
One Broadway, Cambridge, MA 02142, USA